A Phase 3 interventional study of 13vPnC and 23vPS in Vaccines, Pneumococcal Conjugate Vaccine, sponsored by Pfizer. Completed at 47 sites in 10 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2018-12-20.
Sponsored by Pfizer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
People who have received an allogeneic hematopoetic stem cell transplant (HSCT) are more likely than other people to get ill from a germ called Streptococcus pneumoniae. Most people who have had a stem cell transplant are offered a vaccine called 23-valent pneumococcal polysaccharide vaccine (23vPS) to help protect against this germ. The purpose of this study is to evaluate the immune response in HSCT recipients who receive a 13 valent pneumococcal vaccine (13vPnC) followed by 23vPS.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: 13vPnC · Biological: 23vPS
0.5mL 13vPnC dose will be administered intramuscularly into the left limb at visits 1,2,3 and 5. Starting 3-6 months after HSCT 3 doses given at monthly intervals. 4th dose given 6 months after 3rd dose.
0.5mL dose of 23vPS will be administered intramuscularly at visit 6. 23vPS given 1 month after 4th dose of 13vPnC.
Geometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 3 in All Participants
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 1 to 1 month after 13vPnC Dose 3 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before 13vPnC Dose 1 and after 13vPnC Dose 3 blood draws.
Time frame: Before 13vPnC Dose 1 (pre-vaccination), 1 month after 13vPnC Dose 3
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After 13vPnC Dose 3 in Pediatric, Adult and All Participants
Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for pediatric, adult and all participants are presented. GMC (13vPnC) and corresponding 2-sided 95 percent (%) CIs were evaluated. Geometric means were calculated using all participants with available data for 1 month after 13vPnC Dose 3 blood draw. CI for GMC are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
Time frame: 1 month after 13vPnC Dose 3
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After 13vPnC Dose 4 in Pediatric, Adult and All Participants
Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for pediatric, adult and all participants are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for 1 month after 13vPnC Dose 4 blood draw. CI for GMC are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
Time frame: 1 month after 13vPnC Dose 4
Geometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 3 in Pediatric and Adult Participants
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 1 to 1 month after 13vPnC Dose 3 were computed using the logarithmically transformed assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before 13vPnC Dose 1 and after 13vPnC Dose 3 blood draws.
Time frame: Before 13vPnC Dose 1 (pre-vaccination), 1 month after 13vPnC Dose 3
Geometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 4 in Pediatric, Adult and All Participants
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 1 to 1 month after 13vPnC Dose 4 were computed using the logarithmically transformed assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before 13vPnC Dose 1 and after 13vPnC Dose 4 blood draws.
Time frame: Before 13vPnC Dose 1 (pre-vaccination), 1 month after 13vPnC Dose 4
Geometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After 13vPnC Dose 3 to 1 Month After 13vPnC Dose 4 in Pediatric, Adult and All Participants
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 3 to 1 month after 13vPnC Dose 4 were computed using the logarithmically transformed assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both after 13vPnC Dose 3 and after 13vPnC Dose 4 blood draws.
Time frame: 1 month after 13vPnC Dose 3, 1 month after 13vPnC Dose 4
Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Local Reactions: 13vPnC Dose 1
Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 centimeters \[cm\] for participants aged 2 to \<12 years and 2.5 to 5.0 cm for participants aged \>= 12 years); Moderate (2.5 to 7.0 cm for participants aged 2 to \<12 years and 5.5 to 10.0 cm for participants aged \>= 12 years); Severe (greater than \[\>\] 7.0 cm for participants aged 2 to \<12 years and \>10.0 cm for participants aged \>= 12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity).
Time frame: Within 14 days after 13vPnC Dose 1
Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Local Reactions: 13vPnC Dose 2
Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 centimeters \[cm\] for participants aged 2 to \<12 years and 2.5 to 5.0 cm for participants aged \>= 12 years); Moderate (2.5 to 7.0 cm for participants aged 2 to \<12 years and 5.5 to 10.0 cm for participants aged \>= 12 years); Severe (greater than \[\>\] 7.0 cm for participants aged 2 to \<12 years and \>10.0 cm for participants aged \>= 12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity).
Time frame: Within 14 days after 13vPnC Dose 2
Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Local Reactions: 13vPnC Dose 3
Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 centimeters \[cm\] for participants aged 2 to \<12 years and 2.5 to 5.0 cm for participants aged \>= 12 years); Moderate (2.5 to 7.0 cm for participants aged 2 to \<12 years and 5.5 to 10.0 cm for participants aged \>= 12 years); Severe (greater than \[\>\] 7.0 cm for participants aged 2 to \<12 years and \>10.0 cm for participants aged \>= 12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity).
Time frame: Within 14 days after 13vPnC Dose 3
Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Local Reactions: 13vPnC Dose 4
Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 centimeters \[cm\] for participants aged 2 to \<12 years and 2.5 to 5.0 cm for participants aged \>= 12 years); Moderate (2.5 to 7.0 cm for participants aged 2 to \<12 years and 5.5 to 10.0 cm for participants aged \>= 12 years); Severe (greater than \[\>\] 7.0 cm for participants aged 2 to \<12 years and \>10.0 cm for participants aged \>= 12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity).
Time frame: Within 14 days after 13vPnC Dose 4
Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Systemic Events: 13vPnC Dose 1
Specific systemic events (fever \>=38 degrees Celsius \[C\], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (\>2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (\>=6 loose stools in 24 hours).
Time frame: Within 14 days after 13vPnC Dose 1
Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Systemic Events: 13vPnC Dose 2
Specific systemic events (fever \>=38 degrees Celsius \[C\], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (\>2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (\>=6 loose stools in 24 hours).
Time frame: Within 14 days after 13vPnC Dose 2
Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Systemic Events: 13vPnC Dose 3
Specific systemic events (fever \>=38 degrees Celsius \[C\], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (\>2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (\>=6 loose stools in 24 hours).
Time frame: Within 14 days after 13vPnC Dose 3
Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Systemic Events: 13vPnC Dose 4
Specific systemic events (fever \>=38 degrees Celsius \[C\], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (\>2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (\>=6 loose stools in 24 hours).
Time frame: Within 14 days after 13vPnC Dose 4
| Milestone | 13vPnC, 23vPS (Pediatric Participants) | 13vPnC, 23vPS (Adult Participants) |
|---|---|---|
| Started | 61 | 190 |
| Vaccinated 13vpnc dose 1 | 59 | 188 |
| Vaccinated 13vpnc dose 2 | 55 | 176 |
| Vaccinated 13vpnc dose 3 | 54 | 167 |
| Vaccinated 13vpnc dose 4 | 46 | 146 |
| Vaccinated 23vps dose | 45 | 140 |
| Completed | 45 | 139 |
| Not completed | 16 | 51 |
| Withdrew: Adverse event | 13 | 31 |
| Withdrew: Death | 0 | 7 |
| Withdrew: Protocol violation | 2 | 7 |
| Withdrew: Withdrawal by subject | 0 | 4 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Parent/legal guardian request | 1 | 0 |
| Withdrew: Other | 0 | 1 |
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 1 to 1 month after 13vPnC Dose 3 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before 13vPnC Dose 1 and after 13vPnC Dose 3 blood draws.
| fold rise | 13vPnC, 23vPS (All Participants) |
|---|---|
| Serotype 1 (n=191) | 17.96 (13.63 to 23.66) |
| Serotype 3 (n=192) | 5.07 (3.98 to 6.46) |
| Serotype 4 (n=193) | 23.85 (17.61 to 32.30) |
| Serotype 5 (n=194) | 2.99 (2.46 to 3.63) |
| Serotype 6A (n=195) | 5.35 (4.18 to 6.85) |
| Serotype 6B (n=192) | 5.18 (3.99 to 6.74) |
| Serotype 7F (n=195) | 10.28 (8.15 to 12.96) |
| Serotype 9V (n=196) | 5.76 (4.63 to 7.17) |
| Serotype 14 (n=197) | 4.95 (3.72 to 6.58) |
| Serotype 18C (n=196) | 8.22 (6.36 to 10.62) |
| Serotype 19A (n=196) | 3.90 (3.10 to 4.89) |
| Serotype 19F (n=195) | 6.73 (5.15 to 8.78) |
| Serotype 23F (n=197) | 8.01 (6.11 to 10.51) |
Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for pediatric, adult and all participants are presented. GMC (13vPnC) and corresponding 2-sided 95 percent (%) CIs were evaluated. Geometric means were calculated using all participants with available data for 1 month after 13vPnC Dose 3 blood draw. CI for GMC are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
| microgram per milliliter (mcg/mL) | 13vPnC, 23vPS (Pediatric Participants) | 13vPnC, 23vPS (Adult Participants) | 13vPnC, 23vPS (All Participants) |
|---|---|---|---|
| Serotype 1 (n=49, 147, 196) | 3.52 (2.38 to 5.19) | 2.05 (1.53 to 2.76) | 2.35 (1.84 to 2.99) |
| Serotype 3 (n=49, 147, 196) | 1.60 (1.13 to 2.26) | 0.62 (0.49 to 0.79) | 0.79 (0.64 to 0.97) |
| Serotype 4 (n=49, 147, 196) | 4.13 (2.68 to 6.36) | 1.78 (1.35 to 2.34) | 2.20 (1.73 to 2.78) |
| Serotype 5 (n=48, 149, 197) | 4.18 (2.95 to 5.91) | 2.00 (1.60 to 2.51) | 2.39 (1.97 to 2.91) |
| Serotype 6A (n=49, 148, 197) | 7.61 (5.16 to 11.23) | 3.31 (2.53 to 4.33) | 4.07 (3.25 to 5.11) |
| Serotype 6B (n=48, 147, 195) | 6.29 (3.88 to 10.19) | 3.00 (2.25 to 3.98) | 3.60 (2.81 to 4.61) |
| Serotype 7F (n=48, 149, 197) | 7.34 (5.12 to 10.53) | 3.92 (3.08 to 5.00) | 4.57 (3.72 to 5.61) |
| Serotype 9V (n=49, 149, 198) | 4.17 (3.01 to 5.78) | 2.44 (1.93 to 3.10) | 2.79 (2.29 to 3.40) |
| Serotype 14 (n=49, 149, 198) | 6.22 (4.03 to 9.61) | 5.99 (4.35 to 8.26) | 6.05 (4.65 to 7.86) |
| Serotype 18C (n=49, 148, 197) | 4.17 (2.90 to 5.98) | 3.04 (2.37 to 3.91) | 3.29 (2.67 to 4.05) |
| Serotype 19A (n=49, 148, 197) | 8.26 (5.86 to 11.65) | 4.77 (3.77 to 6.04) | 5.47 (4.49 to 6.67) |
| Serotype 19F (n=49, 148, 197) | 5.80 (3.80 to 8.84) | 3.48 (2.69 to 4.50) | 3.95 (3.17 to 4.93) |
| Serotype 23F (n=49, 149, 198) | 6.74 (4.12 to 11.05) | 3.87 (2.85 to 5.26) | 4.44 (3.42 to 5.77) |
Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for pediatric, adult and all participants are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for 1 month after 13vPnC Dose 4 blood draw. CI for GMC are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
| mcg/mL | 13vPnC, 23vPS (Pediatric Participants) | 13vPnC, 23vPS (Adult Participants) | 13vPnC, 23vPS (All Participants) |
|---|---|---|---|
| Serotype 1 (n=38, 123, 161) | 8.75 (5.64 to 13.59) | 4.67 (3.37 to 6.47) | 5.41 (4.13 to 7.10) |
| Serotype 3 (n=38, 123, 161) | 1.23 (0.89 to 1.70) | 0.91 (0.71 to 1.17) | 0.97 (0.79 to 1.20) |
| Serotype 4 (n=36, 124, 160) | 8.41 (5.15 to 13.72) | 4.56 (3.31 to 6.27) | 5.23 (3.99 to 6.86) |
| Serotype 5 (n=38, 122, 160) | 8.43 (6.07 to 11.70) | 5.57 (4.28 to 7.26) | 6.15 (4.95 to 7.64) |
| Serotype 6A (n=37, 122, 159) | 16.33 (10.59 to 25.16) | 12.23 (8.81 to 16.98) | 13.08 (9.99 to 17.13) |
| Serotype 6B (n=38, 124, 162) | 18.13 (11.15 to 29.47) | 12.13 (8.63 to 17.06) | 13.33 (10.04 to 17.70) |
| Serotype 7F (n=38, 124, 162) | 10.37 (7.36 to 14.61) | 8.26 (6.33 to 10.78) | 8.71 (7.00 to 10.83) |
| Serotype 9V (n=37, 124, 161) | 7.78 (5.21 to 11.61) | 5.09 (3.93 to 6.59) | 5.61 (4.50 to 6.98) |
| Serotype 14 (n=37, 124, 161) | 16.04 (10.04 to 25.63) | 12.24 (9.09 to 16.47) | 13.02 (10.13 to 16.74) |
| Serotype 18C (n=38, 122, 160) | 6.54 (4.04 to 10.59) | 6.69 (5.01 to 8.93) | 6.65 (5.20 to 8.51) |
| Serotype 19A (n=37, 124, 161) | 16.94 (11.05 to 25.98) | 12.99 (9.78 to 17.26) | 13.81 (10.88 to 17.52) |
| Serotype 19F (n=38, 123, 161) | 19.96 (12.19 to 32.68) | 13.69 (9.93 to 18.88) | 14.96 (11.42 to 19.61) |
| Serotype 23F (n=38, 123, 161) | 16.65 (10.73 to 25.82) | 12.68 (8.82 to 18.22) | 13.52 (10.07 to 18.15) |
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 1 to 1 month after 13vPnC Dose 3 were computed using the logarithmically transformed assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before 13vPnC Dose 1 and after 13vPnC Dose 3 blood draws.
| fold rise | 13vPnC, 23vPS (Pediatric Participants) | 13vPnC, 23vPS (Adult Participants) |
|---|---|---|
| Serotype 1 (n=48, 143) | 27.64 (16.75 to 45.62) | 15.54 (11.20 to 21.56) |
| Serotype 3 (n=48, 144) | 7.58 (4.74 to 12.13) | 4.43 (3.35 to 5.88) |
| Serotype 4 (n=49, 144) | 40.83 (23.84 to 69.95) | 19.86 (13.83 to 28.52) |
| Serotype 5 (n=47, 147) | 4.11 (2.86 to 5.90) | 2.70 (2.15 to 3.39) |
| Serotype 6A (n=48, 147) | 7.49 (4.79 to 11.72) | 4.79 (3.57 to 6.44) |
| Serotype 6B (n=47, 145) | 6.02 (3.79 to 9.55) | 4.94 (3.60 to 6.77) |
| Serotype 7F (n=48, 147) | 14.65 (9.63 to 22.28) | 9.15 (6.95 to 12.05) |
| Serotype 9V (n=48, 148) | 7.64 (5.40 to 10.82) | 5.26 (4.02 to 6.87) |
| Serotype 14 (n=49, 148) | 5.01 (2.83 to 8.86) | 4.92 (3.53 to 6.87) |
| Serotype 18C (n=49, 147) | 12.59 (7.84 to 20.21) | 7.13 (5.27 to 9.65) |
| Serotype 19A (n=49, 147) | 5.04 (3.38 to 7.51) | 3.58 (2.72 to 4.70) |
| Serotype 19F (n=49, 146) | 7.66 (4.67 to 12.57) | 6.44 (4.69 to 8.85) |
| Serotype 23F (n=49, 148) | 9.73 (5.79 to 16.34) | 7.52 (5.46 to 10.35) |
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 1 to 1 month after 13vPnC Dose 4 were computed using the logarithmically transformed assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before 13vPnC Dose 1 and after 13vPnC Dose 4 blood draws.
| fold rise | 13vPnC, 23vPS (Pediatric Participants) | 13vPnC, 23vPS (Adult Participants) | 13vPnC, 23vPS (All Participants) |
|---|---|---|---|
| Serotype 1 (n=37, 120, 157) | 70.66 (39.20 to 127.36) | 35.81 (25.06 to 51.18) | 42.03 (30.94 to 57.11) |
| Serotype 3 (n=37, 120, 157) | 5.88 (3.25 to 10.61) | 6.41 (4.74 to 8.66) | 6.28 (4.81 to 8.19) |
| Serotype 4 (n=36, 121, 157) | 90.31 (48.05 to 169.77) | 47.47 (32.09 to 70.22) | 55.02 (39.39 to 76.85) |
| Serotype 5 (n=37, 119, 156) | 7.76 (4.81 to 12.51) | 7.29 (5.32 to 9.99) | 7.40 (5.69 to 9.63) |
| Serotype 6A (n=36, 121, 157) | 15.62 (9.63 to 25.34) | 17.02 (11.95 to 24.23) | 16.90 (12.47 to 22.34) |
| Serotype 6B (n=37, 122, 159) | 16.90 (9.76 to 29.25) | 20.09 (13.94 to 28.94) | 19.29 (14.22 to 26.18) |
| Serotype 7F (n=38, 123, 161) | 19.18 (11.75 to 31.33) | 18.69 (13.70 to 25.50) | 18.81 (14.48 to 24.43) |
| Serotype 9V (n=36, 122, 158) | 14.90 (9.55 to 23.25) | 11.13 (8.27 to 14.99) | 11.90 (9.27 to 15.27) |
| Serotype 14 (n=37, 123, 160) | 12.61 (6.47 to 24.56) | 9.69 (6.80 to 13.80) | 10.30 (7.55 to 14.03) |
| Serotype 18C (n=38, 121, 159) | 21.22 (12.05 to 37.36) | 14.40 (10.17 to 20.41) | 15.80 (11.76 to 21.24) |
| Serotype 19A (n=37, 123, 160) | 11.46 (7.22 to 18.20) | 9.52 (6.90 to 13.12) | 9.94 (7.61 to 12.98) |
| Serotype 19F (n=38, 120, 158) | 29.31 (16.63 to 51.64) | 25.63 (17.56 to 37.43) | 26.47 (19.31 to 36.29) |
| Serotype 23F (n=38, 122, 160) | 25.37 (14.69 to 43.83) | 23.02 (15.63 to 33.92) | 23.56 (17.11 to 32.45) |
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 3 to 1 month after 13vPnC Dose 4 were computed using the logarithmically transformed assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both after 13vPnC Dose 3 and after 13vPnC Dose 4 blood draws.
| fold rise | 13vPnC, 23vPS (Pediatric Participants) | 13vPnC, 23vPS (Adult Participants) | 13vPnC, 23vPS (All Participants) |
|---|---|---|---|
| Serotype 1 (n=37, 119, 156) | 2.80 (1.99 to 3.95) | 2.16 (1.65 to 2.82) | 2.30 (1.85 to 2.86) |
| Serotype 3 (n=37, 119, 156) | 0.88 (0.64 to 1.22) | 1.32 (1.07 to 1.62) | 1.20 (1.01 to 1.43) |
| Serotype 4 (n=35, 121, 156) | 2.19 (1.51 to 3.19) | 2.32 (1.88 to 2.86) | 2.29 (1.91 to 2.74) |
| Serotype 5 (n=37, 119, 156) | 2.25 (1.74 to 2.93) | 2.43 (1.94 to 3.06) | 2.39 (1.99 to 2.87) |
| Serotype 6A (n=36, 119, 155) | 2.36 (1.87 to 2.99) | 3.06 (2.35 to 3.98) | 2.88 (2.34 to 3.55) |
| Serotype 6B (n=37, 120, 157) | 2.96 (2.09 to 4.19) | 3.10 (2.44 to 3.95) | 3.07 (2.51 to 3.75) |
| Serotype 7F (n=36, 121, 157) | 1.51 (1.08 to 2.11) | 1.83 (1.47 to 2.29) | 1.75 (1.46 to 2.11) |
| Serotype 9V (n=36, 121, 157) | 2.08 (1.43 to 3.03) | 1.82 (1.48 to 2.23) | 1.88 (1.57 to 2.24) |
| Serotype 14 (n=36, 121, 157) | 2.50 (1.65 to 3.80) | 1.68 (1.32 to 2.13) | 1.84 (1.50 to 2.26) |
| Serotype 18C (n=37, 118, 155) | 1.64 (1.24 to 2.16) | 1.87 (1.54 to 2.28) | 1.81 (1.54 to 2.13) |
| Serotype 19A (n=36, 121, 157) | 2.25 (1.60 to 3.17) | 2.33 (1.91 to 2.85) | 2.31 (1.95 to 2.74) |
| Serotype 19F (n=37, 120, 157) | 3.50 (2.15 to 5.68) | 3.65 (2.90 to 4.59) | 3.61 (2.94 to 4.44) |
| Serotype 23F (n=37, 120, 157) | 2.49 (1.72 to 3.61) | 2.59 (2.04 to 3.30) | 2.57 (2.10 to 3.14) |
Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 centimeters \[cm\] for participants aged 2 to \<12 years and 2.5 to 5.0 cm for participants aged \>= 12 years); Moderate (2.5 to 7.0 cm for participants aged 2 to \<12 years and 5.5 to 10.0 cm for participants aged \>= 12 years); Severe (greater than \[\>\] 7.0 cm for participants aged 2 to \<12 years and \>10.0 cm for participants aged \>= 12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity).
| percentage of participants | 13vPnC, 23vPS (Pediatric Participants) | 13vPnC, 23vPS (Adult Participants) | 13vPnC, 23vPS (All Participants) |
|---|---|---|---|
| Redness: any (n = 38, 130, 168) | 21.1 (9.6 to 37.3) | 11.5 (6.6 to 18.3) | 13.7 (8.9 to 19.8) |
| Redness: mild (n = 38, 130, 168) | 15.8 (6.0 to 31.3) | 10.8 (6.0 to 17.4) | 11.9 (7.4 to 17.8) |
| Redness: moderate (n = 37, 128, 165) | 10.8 (3.0 to 25.4) | 1.6 (0.2 to 5.5) | 3.6 (1.3 to 7.7) |
| Redness: severe (n = 37, 128, 165) | 0.0 (0.0 to 9.5) | 0.0 (0.0 to 2.8) | 0.0 (0.0 to 2.2) |
| Swelling: any (n = 40, 130, 170) | 25.0 (12.7 to 41.2) | 11.5 (6.6 to 18.3) | 14.7 (9.7 to 20.9) |
| Swelling: mild (n = 39, 130, 169) | 10.3 (2.9 to 24.2) | 10.8 (6.0 to 17.4) | 10.7 (6.4 to 16.3) |
| Swelling: moderate (n = 39, 128, 167) | 20.5 (9.3 to 36.5) | 0.8 (0.0 to 4.3) | 5.4 (2.5 to 10.0) |
| Swelling: severe (n = 37, 128, 165) | 0.0 (0.0 to 9.5) | 0.8 (0.0 to 4.3) | 0.6 (0.0 to 3.3) |
| Pain: any (n = 51, 171, 222) | 78.4 (64.7 to 88.7) | 73.1 (65.8 to 79.6) | 74.3 (68.1 to 79.9) |
| Pain: mild (n = 48, 169, 217) | 68.8 (53.7 to 81.3) | 69.8 (62.3 to 76.6) | 69.6 (63.0 to 75.6) |
| Pain: moderate (n = 42, 138, 180) | 45.2 (29.8 to 61.3) | 22.5 (15.8 to 30.3) | 27.8 (21.4 to 34.9) |
| Pain: severe (n = 37, 129, 166) | 5.4 (0.7 to 18.2) | 2.3 (0.5 to 6.6) | 3.0 (1.0 to 6.9) |
Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 centimeters \[cm\] for participants aged 2 to \<12 years and 2.5 to 5.0 cm for participants aged \>= 12 years); Moderate (2.5 to 7.0 cm for participants aged 2 to \<12 years and 5.5 to 10.0 cm for participants aged \>= 12 years); Severe (greater than \[\>\] 7.0 cm for participants aged 2 to \<12 years and \>10.0 cm for participants aged \>= 12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity).
| percentage of participants | 13vPnC, 23vPS (Pediatric Participants) | 13vPnC, 23vPS (Adult Participants) | 13vPnC, 23vPS (All Participants) |
|---|---|---|---|
| Redness: any (n = 28, 109, 137) | 42.9 (24.5 to 62.8) | 16.5 (10.1 to 24.8) | 21.9 (15.3 to 29.8) |
| Redness: mild (n = 26, 108, 134) | 34.6 (17.2 to 55.7) | 15.7 (9.4 to 24.0) | 19.4 (13.1 to 27.1) |
| Redness: moderate (n = 26, 103, 129) | 26.9 (11.6 to 47.8) | 1.9 (0.2 to 6.8) | 7.0 (3.2 to 12.8) |
| Redness: severe (n = 24, 103, 127) | 4.2 (0.1 to 21.1) | 1.0 (0.0 to 5.3) | 1.6 (0.2 to 5.6) |
| Swelling: any (n = 28, 105, 133) | 35.7 (18.6 to 55.9) | 14.3 (8.2 to 22.5) | 18.8 (12.5 to 26.5) |
| Swelling: mild (n = 26, 105, 131) | 15.4 (4.4 to 34.9) | 14.3 (8.2 to 22.5) | 14.5 (9.0 to 21.7) |
| Swelling: moderate (n = 26, 102, 128) | 26.9 (11.6 to 47.8) | 0.0 (0.0 to 3.6) | 5.5 (2.2 to 10.9) |
| Swelling: severe (n = 24, 102, 126) | 0.0 (0.0 to 14.2) | 0.0 (0.0 to 3.6) | 0.0 (0.0 to 2.9) |
| Pain: any (n = 40, 154, 194) | 77.5 (61.5 to 89.2) | 74.7 (67.0 to 81.3) | 75.3 (68.6 to 81.2) |
| Pain: mild (n = 36, 148, 184) | 66.7 (49.0 to 81.4) | 70.9 (62.9 to 78.1) | 70.1 (62.9 to 76.6) |
| Pain: moderate (n = 32, 116, 148) | 53.1 (34.7 to 70.9) | 27.6 (19.7 to 36.7) | 33.1 (25.6 to 41.3) |
| Pain: severe (n = 27, 104, 131) | 14.8 (4.2 to 33.7) | 1.9 (0.2 to 6.8) | 4.6 (1.7 to 9.7) |
Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 centimeters \[cm\] for participants aged 2 to \<12 years and 2.5 to 5.0 cm for participants aged \>= 12 years); Moderate (2.5 to 7.0 cm for participants aged 2 to \<12 years and 5.5 to 10.0 cm for participants aged \>= 12 years); Severe (greater than \[\>\] 7.0 cm for participants aged 2 to \<12 years and \>10.0 cm for participants aged \>= 12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity).
| percentage of participants | 13vPnC, 23vPS (Pediatric Participants) | 13vPnC, 23vPS (Adult Participants) | 13vPnC, 23vPS (All Participants) |
|---|---|---|---|
| Redness: any (n = 25, 95, 120) | 32.0 (14.9 to 53.5) | 9.5 (4.4 to 17.2) | 14.2 (8.5 to 21.7) |
| Redness: mild (n = 24, 94, 118) | 20.8 (7.1 to 42.2) | 8.5 (3.7 to 16.1) | 11.0 (6.0 to 18.1) |
| Redness: moderate (n = 24, 93, 117) | 20.8 (7.1 to 42.2) | 1.1 (0.0 to 5.8) | 5.1 (1.9 to 10.8) |
| Redness: severe (n = 23, 93, 116) | 4.3 (0.1 to 21.9) | 1.1 (0.0 to 5.8) | 1.7 (0.2 to 6.1) |
| Swelling: any (n = 28, 93, 121) | 35.7 (18.6 to 55.9) | 8.6 (3.8 to 16.2) | 14.9 (9.1 to 22.5) |
| Swelling: mild (n = 27, 93, 120) | 25.9 (11.1 to 46.3) | 8.6 (3.8 to 16.2) | 12.5 (7.2 to 19.8) |
| Swelling: moderate (n = 25, 92, 117) | 20.0 (6.8 to 40.7) | 0.0 (0.0 to 3.9) | 4.3 (1.4 to 9.7) |
| Swelling: severe (n = 23, 92, 115) | 4.3 (0.1 to 21.9) | 0.0 (0.0 to 3.9) | 0.9 (0.0 to 4.7) |
| Pain: any (n = 37, 138, 175) | 70.3 (53.0 to 84.1) | 73.2 (65.0 to 80.4) | 72.6 (65.3 to 79.0) |
| Pain: mild (n = 31, 132, 163) | 64.5 (45.4 to 80.8) | 67.4 (58.7 to 75.3) | 66.9 (59.1 to 74.0) |
| Pain: moderate (n = 34, 107, 141) | 38.2 (22.2 to 56.4) | 27.1 (19.0 to 36.6) | 29.8 (22.4 to 38.1) |
| Pain: severe (n = 24, 93, 117) | 8.3 (1.0 to 27.0) | 3.2 (0.7 to 9.1) | 4.3 (1.4 to 9.7) |
Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 centimeters \[cm\] for participants aged 2 to \<12 years and 2.5 to 5.0 cm for participants aged \>= 12 years); Moderate (2.5 to 7.0 cm for participants aged 2 to \<12 years and 5.5 to 10.0 cm for participants aged \>= 12 years); Severe (greater than \[\>\] 7.0 cm for participants aged 2 to \<12 years and \>10.0 cm for participants aged \>= 12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity).
| percentage of participants | 13vPnC, 23vPS (Pediatric Participants) | 13vPnC, 23vPS (Adult Participants) | 13vPnC, 23vPS (All Participants) |
|---|---|---|---|
| Redness: any (n = 21, 79, 100) | 71.4 (47.8 to 88.7) | 22.8 (14.1 to 33.6) | 33.0 (23.9 to 43.1) |
| Redness: mild (n = 20, 77, 97) | 50.0 (27.2 to 72.8) | 15.6 (8.3 to 25.6) | 22.7 (14.8 to 32.3) |
| Redness: moderate (n = 18, 72, 90) | 50.0 (26.0 to 74.0) | 9.7 (4.0 to 19.0) | 17.8 (10.5 to 27.3) |
| Redness: severe (n = 16, 73, 89) | 12.5 (1.6 to 38.3) | 4.1 (0.9 to 11.5) | 5.6 (1.8 to 12.6) |
| Swelling: any (n = 27, 81, 108) | 66.7 (46.0 to 83.5) | 28.4 (18.9 to 39.5) | 38.0 (28.8 to 47.8) |
| Swelling: mild (n = 21, 79, 100) | 38.1 (18.1 to 61.6) | 21.5 (13.1 to 32.2) | 25.0 (16.9 to 34.7) |
| Swelling: moderate (n = 23, 72, 95) | 52.2 (30.6 to 73.2) | 6.9 (2.3 to 15.5) | 17.9 (10.8 to 27.1) |
| Swelling: severe (n = 15, 73, 88) | 6.7 (0.2 to 31.9) | 4.1 (0.9 to 11.5) | 4.5 (1.3 to 11.2) |
| Pain: any (n = 30, 113, 143) | 86.7 (69.3 to 96.2) | 77.0 (68.1 to 84.4) | 79.0 (71.4 to 85.4) |
| Pain: mild (n = 25, 105, 130) | 76.0 (54.9 to 90.6) | 71.4 (61.8 to 79.8) | 72.3 (63.8 to 79.8) |
| Pain: moderate (n = 24, 85, 109) | 62.5 (40.6 to 81.2) | 31.8 (22.1 to 42.8) | 38.5 (29.4 to 48.3) |
| Pain: severe (n = 16, 74, 90) | 12.5 (1.6 to 38.3) | 5.4 (1.5 to 13.3) | 6.7 (2.5 to 13.9) |
Specific systemic events (fever \>=38 degrees Celsius \[C\], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (\>2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (\>=6 loose stools in 24 hours).
| percentage of participants | 13vPnC, 23vPS (Pediatric Participants) | 13vPnC, 23vPS (Adult Participants) | 13vPnC, 23vPS (All Participants) |
|---|---|---|---|
| Fever: >=38 degrees C (n = 39, 130, 169) | 12.8 (4.3 to 27.4) | 6.2 (2.7 to 11.8) | 7.7 (4.2 to 12.8) |
| Fever: >=38, <38.5 degrees C (n = 37, 130, 167) | 5.4 (0.7 to 18.2) | 6.2 (2.7 to 11.8) | 6.0 (2.9 to 10.7) |
| Fever: >=38.5, <39 degrees C (n = 37, 128, 165) | 5.4 (0.7 to 18.2) | 0.0 (0.0 to 2.8) | 1.2 (0.1 to 4.3) |
| Fever: >=39, =<40 degrees C (n = 39, 128, 167) | 7.7 (1.6 to 20.9) | 0.0 (0.0 to 2.8) | 1.8 (0.4 to 5.2) |
| Fever: >40 degrees C (n = 37, 128, 165) | 0.0 (0.0 to 9.5) | 0.0 (0.0 to 2.8) | 0.0 (0.0 to 2.2) |
| Fatigue: Any (n = 45, 159, 204) | 53.3 (37.9 to 68.3) | 59.7 (51.7 to 67.4) | 58.3 (51.2 to 65.2) |
| Fatigue: Mild (n = 41, 149, 190) | 36.6 (22.1 to 53.1) | 49.0 (40.7 to 57.3) | 46.3 (39.1 to 53.7) |
| Fatigue: Moderate (n = 44, 148, 192) | 36.4 (22.4 to 52.2) | 35.8 (28.1 to 44.1) | 35.9 (29.2 to 43.2) |
| Fatigue: Severe (n = 37, 136, 173) | 10.8 (3.0 to 25.4) | 11.8 (6.9 to 18.4) | 11.6 (7.2 to 17.3) |
| Headache: Any (n = 42, 147, 189) | 45.2 (29.8 to 61.3) | 44.2 (36.0 to 52.6) | 44.4 (37.2 to 51.8) |
| Headache: Mild (n = 41, 145, 186) | 39.0 (24.2 to 55.5) | 37.9 (30.0 to 46.4) | 38.2 (31.2 to 45.6) |
| Headache: Moderate (n = 40, 134, 174) | 20.0 (9.1 to 35.6) | 17.2 (11.2 to 24.6) | 17.8 (12.4 to 24.3) |
| Headache: Severe (n = 37, 130, 167) | 2.7 (0.1 to 14.2) | 2.3 (0.5 to 6.6) | 2.4 (0.7 to 6.0) |
| Vomiting: Any (n = 39, 134, 173) | 20.5 (9.3 to 36.5) | 20.9 (14.4 to 28.8) | 20.8 (15.0 to 27.6) |
| Vomiting: Mild (n = 38, 134, 172) | 18.4 (7.7 to 34.3) | 17.9 (11.8 to 25.5) | 18.0 (12.6 to 24.6) |
| Vomiting: Moderate (n = 38, 128, 166) | 2.6 (0.1 to 13.8) | 3.9 (1.3 to 8.9) | 3.6 (1.3 to 7.7) |
| Vomiting: Severe (n = 37, 128, 165) | 5.4 (0.7 to 18.2) | 0.0 (0.0 to 2.8) | 1.2 (0.1 to 4.3) |
| Diarrhea: Any (n = 44, 145, 189) | 31.8 (18.6 to 47.6) | 35.9 (28.1 to 44.2) | 34.9 (28.1 to 42.2) |
| Diarrhea: Mild (n = 44, 142, 186) | 31.8 (18.6 to 47.6) | 33.8 (26.1 to 42.2) | 33.3 (26.6 to 40.6) |
| Diarrhea: Moderate (n = 38, 133, 171) | 5.3 (0.6 to 17.7) | 9.0 (4.7 to 15.2) | 8.2 (4.5 to 13.4) |
| Diarrhea: Severe (n = 37, 131, 168) | 0.0 (0.0 to 9.5) | 3.8 (1.3 to 8.7) | 3.0 (1.0 to 6.8) |
| Muscle Pain: Any (n = 47, 154, 201) | 55.3 (40.1 to 69.8) | 50.0 (41.8 to 58.2) | 51.2 (44.1 to 58.3) |
| Muscle Pain: Mild (n = 43, 148, 191) | 46.5 (31.2 to 62.3) | 42.6 (34.5 to 51.0) | 43.5 (36.3 to 50.8) |
| Muscle Pain: Moderate (n = 44, 139, 183) | 36.4 (22.4 to 52.2) | 21.6 (15.1 to 29.4) | 25.1 (19.0 to 32.1) |
| Muscle Pain: Severe (n = 37, 131, 168) | 5.4 (0.7 to 18.2) | 5.3 (2.2 to 10.7) | 5.4 (2.5 to 9.9) |
| Joint Pain: Any (n = 38, 143, 181) | 26.3 (13.4 to 43.1) | 26.6 (19.5 to 34.6) | 26.5 (20.2 to 33.6) |
| Joint Pain: Mild (n = 37, 139, 176) | 18.9 (8.0 to 35.2) | 19.4 (13.2 to 27.0) | 19.3 (13.8 to 25.9) |
| Joint Pain: Moderate (n = 38, 137, 175) | 15.8 (6.0 to 31.3) | 14.6 (9.2 to 21.6) | 14.9 (9.9 to 21.0) |
| Joint Pain: Severe (n = 37, 130, 167) | 2.7 (0.1 to 14.2) | 3.1 (0.8 to 7.7) | 3.0 (1.0 to 6.8) |
| Use of Medication to Treat Pain (n= 40, 136, 176) | 25.0 (12.7 to 41.2) | 13.2 (8.0 to 20.1) | 15.9 (10.8 to 22.2) |
| Use of Medication to Treat Fever (n= 41, 133, 174) | 24.4 (12.4 to 40.3) | 14.3 (8.8 to 21.4) | 16.7 (11.5 to 23.1) |
Specific systemic events (fever \>=38 degrees Celsius \[C\], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (\>2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (\>=6 loose stools in 24 hours).
| percentage of participants | 13vPnC, 23vPS (Pediatric Participants) | 13vPnC, 23vPS (Adult Participants) | 13vPnC, 23vPS (All Participants) |
|---|---|---|---|
| Fever: >=38 degrees C (n = 26, 105, 131) | 23.1 (9.0 to 43.6) | 6.7 (2.7 to 13.3) | 9.9 (5.4 to 16.4) |
| Fever: >=38, <38.5 degrees C (n = 26, 105, 131) | 19.2 (6.6 to 39.4) | 5.7 (2.1 to 12.0) | 8.4 (4.3 to 14.5) |
| Fever: >=38.5, <39 degrees C (n = 24, 102, 126) | 8.3 (1.0 to 27.0) | 1.0 (0.0 to 5.3) | 2.4 (0.5 to 6.8) |
| Fever: >=39, =<40 degrees C (n = 24, 102, 126) | 8.3 (1.0 to 27.0) | 1.0 (0.0 to 5.3) | 2.4 (0.5 to 6.8) |
| Fever: >40 degrees C (n = 24, 102, 126) | 0.0 (0.0 to 14.2) | 0.0 (0.0 to 3.6) | 0.0 (0.0 to 2.9) |
| Fatigue: Any (n = 38, 133, 171) | 60.5 (43.4 to 76.0) | 56.4 (47.5 to 65.0) | 57.3 (49.5 to 64.8) |
| Fatigue: Mild (n = 31, 125, 156) | 45.2 (27.3 to 64.0) | 39.2 (30.6 to 48.3) | 40.4 (32.6 to 48.5) |
| Fatigue: Moderate (n = 33, 122, 155) | 45.5 (28.1 to 63.6) | 37.7 (29.1 to 46.9) | 39.4 (31.6 to 47.5) |
| Fatigue: Severe (n = 24, 107, 131) | 12.5 (2.7 to 32.4) | 9.3 (4.6 to 16.5) | 9.9 (5.4 to 16.4) |
| Headache: Any (n = 31, 121,152) | 32.3 (16.7 to 51.4) | 35.5 (27.0 to 44.8) | 34.9 (27.3 to 43.0) |
| Headache: Mild (n = 30, 117, 147) | 30.0 (14.7 to 49.4) | 29.9 (21.8 to 39.1) | 29.9 (22.7 to 38.0) |
| Headache: Moderate (n = 26, 110, 136) | 7.7 (0.9 to 25.1) | 16.4 (10.0 to 24.6) | 14.7 (9.2 to 21.8) |
| Headache: Severe (n = 24, 104, 128) | 0.0 (0.0 to 14.2) | 1.9 (0.2 to 6.8) | 1.6 (0.2 to 5.5) |
| Vomiting: Any (n = 28, 107, 135) | 21.4 (8.3 to 41.0) | 13.1 (7.3 to 21.0) | 14.8 (9.3 to 21.9) |
| Vomiting: Mild (n = 27, 107, 134) | 18.5 (6.3 to 38.1) | 10.3 (5.2 to 17.7) | 11.9 (7.0 to 18.7) |
| Vomiting: Moderate (n = 28, 103, 131) | 14.3 (4.0 to 32.7) | 4.9 (1.6 to 11.0) | 6.9 (3.2 to 12.6) |
| Vomiting: Severe (n = 24, 102, 126) | 0.0 (0.0 to 14.2) | 1.0 (0.0 to 5.3) | 0.8 (0.0 to 4.3) |
| Diarrhea: Any (n = 29, 121, 150) | 31.0 (15.3 to 50.8) | 28.9 (21.0 to 37.9) | 29.3 (22.2 to 37.3) |
| Diarrhea: Mild (n = 29, 120, 149) | 31.0 (15.3 to 50.8) | 26.7 (19.0 to 35.5) | 27.5 (20.5 to 35.4) |
| Diarrhea: Moderate (n = 25, 109, 134) | 8.0 (1.0 to 26.0) | 10.1 (5.1 to 17.3) | 9.7 (5.3 to 16.0) |
| Diarrhea: Severe (n = 24, 103, 127) | 0.0 (0.0 to 14.2) | 1.9 (0.2 to 6.8) | 1.6 (0.2 to 5.6) |
| Muscle Pain: Any (n = 36, 124, 160) | 44.4 (27.9 to 61.9) | 45.2 (36.2 to 54.3) | 45.0 (37.1 to 53.1) |
| Muscle Pain: Mild (n = 32, 118, 150) | 31.3 (16.1 to 50.0) | 37.3 (28.6 to 46.7) | 36.0 (28.3 to 44.2) |
| Muscle Pain: Moderate (n = 32, 111, 143) | 37.5 (21.1 to 56.3) | 25.2 (17.5 to 34.4) | 28.0 (20.8 to 36.1) |
| Muscle Pain: Severe (n = 25, 106, 131) | 8.0 (1.0 to 26.0) | 5.7 (2.1 to 11.9) | 6.1 (2.7 to 11.7) |
| Joint Pain: Any (n = 31, 116, 147) | 32.3 (16.7 to 51.4) | 23.3 (15.9 to 32.0) | 25.2 (18.4 to 33.0) |
| Joint Pain: Mild (n = 27, 115, 142) | 18.5 (6.3 to 38.1) | 21.7 (14.6 to 30.4) | 21.1 (14.7 to 28.8) |
| Joint Pain: Moderate (n = 30, 106, 136) | 30.0 (14.7 to 49.4) | 10.4 (5.3 to 17.8) | 14.7 (9.2 to 21.8) |
| Joint Pain: Severe (n = 25, 104, 129) | 4.0 (0.1 to 20.4) | 1.9 (0.2 to 6.8) | 2.3 (0.5 to 6.6) |
| Use of Medication to Treat Pain (n= 28, 105, 133) | 25.0 (10.7 to 44.9) | 7.6 (3.3 to 14.5) | 11.3 (6.5 to 17.9) |
| Use of Medication to Treat Fever (n= 27, 107, 134) | 33.3 (16.5 to 54.0) | 10.3 (5.2 to 17.7) | 14.9 (9.4 to 22.1) |
Specific systemic events (fever \>=38 degrees Celsius \[C\], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (\>2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (\>=6 loose stools in 24 hours).
| percentage of participants | 13vPnC, 23vPS (Pediatric Participants) | 13vPnC, 23vPS (Adult Participants) | 13vPnC, 23vPS (All Participants) |
|---|---|---|---|
| Fever: >=38 degrees C (n = 27, 93, 120) | 14.8 (4.2 to 33.7) | 4.3 (1.2 to 10.6) | 6.7 (2.9 to 12.7) |
| Fever: >=38, <38.5 degrees C (n = 26, 93, 119) | 11.5 (2.4 to 30.2) | 3.2 (0.7 to 9.1) | 5.0 (1.9 to 10.7) |
| Fever: >=38.5, <39 degrees C (n = 24, 93, 117) | 4.2 (0.1 to 21.1) | 3.2 (0.7 to 9.1) | 3.4 (0.9 to 8.5) |
| Fever: >=39, =<40 degrees C (n = 24, 92, 116) | 4.2 (0.1 to 21.1) | 1.1 (0.0 to 5.9) | 1.7 (0.2 to 6.1) |
| Fever: >40 degrees C (n = 23, 92, 115) | 0.0 (0.0 to 14.8) | 0.0 (0.0 to 3.9) | 0.0 (0.0 to 3.2) |
| Fatigue: Any (n = 35, 122, 157) | 48.6 (31.4 to 66.0) | 49.2 (40.0 to 58.4) | 49.0 (41.0 to 57.1) |
| Fatigue: Mild (n = 32, 116, 148) | 40.6 (23.7 to 59.4) | 38.8 (29.9 to 48.3) | 39.2 (31.3 to 47.5) |
| Fatigue: Moderate (n = 30, 107, 137) | 33.3 (17.3 to 52.8) | 29.9 (21.4 to 39.5) | 30.7 (23.1 to 39.1) |
| Fatigue: Severe (n = 24, 96, 120) | 4.2 (0.1 to 21.1) | 7.3 (3.0 to 14.4) | 6.7 (2.9 to 12.7) |
| Headache: Any (n = 32, 110,142) | 37.5 (21.1 to 56.3) | 37.3 (28.2 to 47.0) | 37.3 (29.4 to 45.8) |
| Headache: Mild (n = 30, 108, 138) | 30.0 (14.7 to 49.4) | 32.4 (23.7 to 42.1) | 31.9 (24.2 to 40.4) |
| Headache: Moderate (n = 27, 95, 122) | 22.2 (8.6 to 42.3) | 15.8 (9.1 to 24.7) | 17.2 (11.0 to 25.1) |
| Headache: Severe (n = 25, 94, 119) | 8.0 (1.0 to 26.0) | 2.1 (0.3 to 7.5) | 3.4 (0.9 to 8.4) |
| Vomiting: Any (n = 25, 95, 120) | 8.0 (1.0 to 26.0) | 11.6 (5.9 to 19.8) | 10.8 (5.9 to 17.8) |
| Vomiting: Mild (n = 24, 95, 119) | 4.2 (0.1 to 21.1) | 5.3 (1.7 to 11.9) | 5.0 (1.9 to 10.7) |
| Vomiting: Moderate (n = 24, 93, 117) | 4.2 (0.1 to 21.1) | 7.5 (3.1 to 14.9) | 6.8 (3.0 to 13.0) |
| Vomiting: Severe (n = 23, 92, 115) | 0.0 (0.0 to 14.8) | 0.0 (0.0 to 3.9) | 0.0 (0.0 to 3.2) |
| Diarrhea: Any (n = 26, 104, 130) | 15.4 (4.4 to 34.9) | 25.0 (17.0 to 34.4) | 23.1 (16.1 to 31.3) |
| Diarrhea: Mild (n = 26, 102, 128) | 15.4 (4.4 to 34.9) | 21.6 (14.0 to 30.8) | 20.3 (13.7 to 28.3) |
| Diarrhea: Moderate (n = 24, 95, 119) | 4.2 (0.1 to 21.1) | 5.3 (1.7 to 11.9) | 5.0 (1.9 to 10.7) |
| Diarrhea: Severe (n = 23, 94, 117) | 0.0 (0.0 to 14.8) | 2.1 (0.3 to 7.5) | 1.7 (0.2 to 6.0) |
| Muscle Pain: Any (n = 35, 117, 152) | 45.7 (28.8 to 63.4) | 38.5 (29.6 to 47.9) | 40.1 (32.3 to 48.4) |
| Muscle Pain: Mild (n = 30, 112, 142) | 33.3 (17.3 to 52.8) | 33.0 (24.4 to 42.6) | 33.1 (25.4 to 41.5) |
| Muscle Pain: Moderate (n = 31, 101, 132) | 32.3 (16.7 to 51.4) | 16.8 (10.1 to 25.6) | 20.5 (13.9 to 28.3) |
| Muscle Pain: Severe (n = 24, 94, 118) | 4.2 (0.1 to 21.1) | 3.2 (0.7 to 9.0) | 3.4 (0.9 to 8.5) |
| Joint Pain: Any (n = 28, 104, 132) | 25.0 (10.7 to 44.9) | 20.2 (13.0 to 29.2) | 21.2 (14.6 to 29.2) |
| Joint Pain: Mild (n = 26, 102, 128) | 19.2 (6.6 to 39.4) | 17.6 (10.8 to 26.4) | 18.0 (11.7 to 25.7) |
| Joint Pain: Moderate (n = 27, 95, 122) | 18.5 (6.3 to 38.1) | 8.4 (3.7 to 15.9) | 10.7 (5.8 to 17.5) |
| Joint Pain: Severe (n = 25, 94, 119) | 8.0 (1.0 to 26.0) | 2.1 (0.3 to 7.5) | 3.4 (0.9 to 8.4) |
| Use of Medication to Treat Pain (n= 28, 97, 125) | 21.4 (8.3 to 41.0) | 12.4 (6.6 to 20.6) | 14.4 (8.8 to 21.8) |
| Use of Medication to Treat Fever (n= 30, 101, 131) | 26.7 (12.3 to 45.9) | 15.8 (9.3 to 24.4) | 18.3 (12.1 to 26.0) |
Specific systemic events (fever \>=38 degrees Celsius \[C\], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (\>2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (\>=6 loose stools in 24 hours).
| percentage of participants | 13vPnC, 23vPS (Pediatric Participants) | 13vPnC, 23vPS (Adult Participants) | 13vPnC, 23vPS (All Participants) |
|---|---|---|---|
| Fever: >=38 degrees C (n= 18, 78, 96) | 27.8 (9.7 to 53.5) | 15.4 (8.2 to 25.3) | 17.7 (10.7 to 26.8) |
| Fever: >=38, <38.5 degrees C (n = 16, 76, 92) | 12.5 (1.6 to 38.3) | 13.2 (6.5 to 22.9) | 13.0 (6.9 to 21.7) |
| Fever: >=38.5, <39 degrees C (n = 17, 73, 90) | 17.6 (3.8 to 43.4) | 2.7 (0.3 to 9.5) | 5.6 (1.8 to 12.5) |
| Fever: >=39, =<40 degrees C (n = 15, 72, 87) | 0.0 (0.0 to 21.8) | 2.8 (0.3 to 9.7) | 2.3 (0.3 to 8.1) |
| Fever: >40 degrees C (n = 15, 71, 86) | 0.0 (0.0 to 21.8) | 0.0 (0.0 to 5.1) | 0.0 (0.0 to 4.2) |
| Fatigue: Any (n = 28, 100, 128) | 67.9 (47.6 to 84.1) | 67.0 (56.9 to 76.1) | 67.2 (58.3 to 75.2) |
| Fatigue: Mild (n = 26, 95, 121) | 61.5 (40.6 to 79.8) | 54.7 (44.2 to 65.0) | 56.2 (46.9 to 65.2) |
| Fatigue: Moderate (n = 20, 86, 106) | 45.0 (23.1 to 68.5) | 45.3 (34.6 to 56.5) | 45.3 (35.6 to 55.2) |
| Fatigue: Severe (n = 16, 77, 93) | 12.5 (1.6 to 38.3) | 13.0 (6.4 to 22.6) | 12.9 (6.8 to 21.5) |
| Headache: Any (n = 21, 93, 114) | 52.4 (29.8 to 74.3) | 45.2 (34.8 to 55.8) | 46.5 (37.1 to 56.1) |
| Headache: Mild (n = 21, 88, 109) | 47.6 (25.7 to 70.2) | 38.6 (28.4 to 49.6) | 40.4 (31.1 to 50.2) |
| Headache: Moderate (n = 16, 82, 98) | 18.8 (4.0 to 45.6) | 28.0 (18.7 to 39.1) | 26.5 (18.1 to 36.4) |
| Headache: Severe (n = 16, 74, 90) | 12.5 (1.6 to 38.3) | 5.4 (1.5 to 13.3) | 6.7 (2.5 to 13.9) |
| Vomiting: Any (n = 16, 73, 89) | 6.3 (0.2 to 30.2) | 5.5 (1.5 to 13.4) | 5.6 (1.8 to 12.6) |
| Vomiting: Mild (n = 16, 73, 89) | 6.3 (0.2 to 30.2) | 5.5 (1.5 to 13.4) | 5.6 (1.8 to 12.6) |
| Vomiting: Moderate (n = 15, 71, 86) | 0.0 (0.0 to 21.8) | 0.0 (0.0 to 5.1) | 0.0 (0.0 to 4.2) |
| Vomiting: Severe (n = 15, 71, 86) | 0.0 (0.0 to 21.8) | 0.0 (0.0 to 5.1) | 0.0 (0.0 to 4.2) |
| Diarrhea: Any (n = 18, 83, 101) | 22.2 (6.4 to 47.6) | 30.1 (20.5 to 41.2) | 28.7 (20.1 to 38.6) |
| Diarrhea: Mild (n = 18, 82, 100) | 22.2 (6.4 to 47.6) | 29.3 (19.7 to 40.4) | 28.0 (19.5 to 37.9) |
| Diarrhea: Moderate (n = 15, 72, 87) | 0.0 (0.0 to 21.8) | 4.2 (0.9 to 11.7) | 3.4 (0.7 to 9.7) |
| Diarrhea: Severe (n = 15, 72, 87) | 0.0 (0.0 to 21.8) | 1.4 (0.0 to 7.5) | 1.1 (0.0 to 6.2) |
| Muscle Pain: Any (n = 24, 99, 123) | 58.3 (36.6 to 77.9) | 60.6 (50.3 to 70.3) | 60.2 (50.9 to 68.9) |
| Muscle Pain: Mild (n = 22, 92, 114) | 50.0 (28.2 to 71.8) | 50.0 (39.4 to 60.6) | 50.0 (40.5 to 59.5) |
| Muscle Pain: Moderate (n = 19, 80, 99) | 36.8 (16.3 to 61.6) | 30.0 (20.3 to 41.3) | 31.3 (22.4 to 41.4) |
| Muscle Pain: Severe (n = 16, 75, 91) | 12.5 (1.6 to 38.3) | 6.7 (2.2 to 14.9) | 7.7 (3.1 to 15.2) |
| Joint Pain: Any (n = 16, 83, 99) | 25.0 (7.3 to 52.4) | 32.5 (22.6 to 43.7) | 31.3 (22.4 to 41.4) |
| Joint Pain: Mild (n = 15, 78, 93) | 13.3 (1.7 to 40.5) | 24.4 (15.3 to 35.4) | 22.6 (14.6 to 32.4) |
| Joint Pain: Moderate (n = 16, 75, 91) | 12.5 (1.6 to 38.3) | 17.3 (9.6 to 27.8) | 16.5 (9.5 to 25.7) |
| Joint Pain: Severe (n = 16, 74, 90) | 6.3 (0.2 to 30.2) | 4.1 (0.8 to 11.4) | 4.4 (1.2 to 11.0) |
| Use of Medication to Treat Pain (n= 16, 77, 93) | 18.8 (4.0 to 45.6) | 16.9 (9.3 to 27.1) | 17.2 (10.2 to 26.4) |
| Use of Medication to Treat Fever (n= 17, 77, 94) | 23.5 (6.8 to 49.9) | 15.6 (8.3 to 25.6) | 17.0 (10.1 to 26.2) |
Collected over AEs/SAEs: recorded from 13vPnC Dose 1 to completion of study. Participants recorded pre-specified AEs in electronic diary:local reactions; systemic events (up to 14 days after 13vPnC vaccination). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 13vPnC Dose 1 to 13vPnC Dose 3 Blood Draw | — | 58/247 (23.5%) | 203/247 (82.2%) |
| 13vPnC Dose 3 Blood Draw to 13vPnC Dose 4 | — | 42/221 (19%) | 89/221 (40.3%) |
| 13vPnC Dose 4 | — | 11/192 (5.7%) | 127/192 (66.1%) |
| 23vPS Dose | — | 11/184 (6%) | 93/184 (50.5%) |
| Follow-up | — | 28/247 (11.3%) | 19/247 (7.7%) |
| Event | 13vPnC Dose 1 to 13vPnC Dose 3 Blood Draw | 13vPnC Dose 3 Blood Draw to 13vPnC Dose 4 | 13vPnC Dose 4 | 23vPS Dose | Follow-up |
|---|---|---|---|---|---|
| PyrexiaGeneral disorders | 6/247 | 4/221 | 0/192 | 0/184 | 4/247 |
| Acute myeloid leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 6/247 | 2/221 | 0/192 | 0/184 | 0/247 |
| Acute myeloid leukaemia recurrentNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 6/247 | 4/221 | 1/192 | 0/184 | 3/247 |
| Graft versus host diseaseImmune system disorders | 5/247 | 1/221 | 0/192 | 0/184 | 2/247 |
| Herpes zosterInfections and infestations | 2/247 | 4/221 | 1/192 | 1/184 | 2/247 |
| PneumoniaInfections and infestations | 2/247 | 2/221 | 1/192 | 0/184 | 4/247 |
| Graft versus host disease in liverImmune system disorders | 1/247 | 1/221 | 0/192 | 2/184 | 0/247 |
| Graft versus host disease in skinImmune system disorders | 1/247 | 2/221 | 0/192 | 0/184 | 0/247 |
| Escherichia sepsisInfections and infestations | 2/247 | 2/221 | 0/192 | 0/184 | 0/247 |
| Bronchopulmonary aspergillosisInfections and infestations | 1/247 | 2/221 | 0/192 | 0/184 | 0/247 |
| Event | 13vPnC Dose 1 to 13vPnC Dose 3 Blood Draw | 13vPnC Dose 3 Blood Draw to 13vPnC Dose 4 | 13vPnC Dose 4 | 23vPS Dose | Follow-up |
|---|---|---|---|---|---|
| Pain (Any)Skin and subcutaneous tissue disorders | 165/222 | — | 113/143 | — | — |
| Pain (Any)Skin and subcutaneous tissue disorders | 146/194 | — | — | — | — |
| Pain (Any)Skin and subcutaneous tissue disorders | 127/175 | — | — | — | — |
| Pain (Mild)Skin and subcutaneous tissue disorders | 151/217 | — | 94/130 | — | — |
| Pain (Mild)Skin and subcutaneous tissue disorders | 129/184 | — | — | — | — |
| Fatigue (Any)General disorders | 119/204 | — | 86/128 | — | — |
| Pain (Mild)Skin and subcutaneous tissue disorders | 109/163 | — | — | — | — |
| Muscle pain (Any)General disorders | 103/201 | — | 74/123 | — | — |
| Fatigue (Any)General disorders | 98/171 | — | — | — | — |
| Fatigue (Mild)General disorders | 88/190 | — | 68/121 | — | — |
Safety population included all participants who received at least 1 dose of investigational product and had safety data available.
| Age, Continuous(years) | 13vPnC, 23vPS (Pediatric Participants) | 13vPnC, 23vPS (Adult Participants) | Total |
|---|---|---|---|
| Mean | 10.3 ± 4.41 | 47.3 ± 12.39 | 38.4 ± 19.26 |
| Sex: Female, Male(Participants) | 13vPnC, 23vPS (Pediatric Participants) | 13vPnC, 23vPS (Adult Participants) | Total |
|---|---|---|---|
| Female | 26 | 74 | 100 |
| Male | 33 | 114 | 147 |
Ran from Jan 2010 to primary completion in May 2013, 39 months.
Results were first posted in Apr 2014, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine